

## Faculty Bio



### **Aung Naing, MD, FACP**

(he/him/his)

Professor, Investigational Cancer Therapeutics

The University of Texas MD Anderson Cancer Center

Houston, TX

Editor-in-Chief, *Journal of Immunotherapy and Precision Oncology*

Aung Naing, MD, FACP, is Professor and Lead of the Immunotherapy Working Group in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. Dr. Naing has extensive experience developing first-in-human, early-phase clinical trials including several immunotherapy-based trials.

Dr. Naing's research focuses on clinical translation of basic immunobiology and is aimed at identifying biomarkers to predict response, resistance, and immune-related adverse events associated with immunotherapies. He has authored and co-authored more than 270 original research articles in high-impact journals such as *Cell*, *Lancet Oncology*, *Cancer Cell*, and *Journal of Clinical Oncology*. Recently, he edited the fourth edition of the book entitled "Immunotherapy" published by Springer International Publishing AG. He also serves as the course director for a Tumor Immunology course at the University of Texas Graduate School of Biomedical Sciences.

As an expert in developmental therapeutics, Dr. Naing has served as a discussant for poster presentations in ASCO, AACR and SITC annual meetings. He has also served as a member on several working groups and review boards. Notably, he led the skin toxicities working group and served as a member of the gastrointestinal toxicity working group of the ASCO management of immune-mediated side effects guideline panel that developed the clinical practice guidelines on the management of immune-mediated side effects associated with immunotherapy. Dr. Naing is also a member of the SITC Immune Biomarkers Task Force, which functions with a goal of identifying the critical next steps in obtaining and handling biospecimens, biomarker identification, data and specimen sharing, and multi-disciplinary collaboration. He spearheaded MD Anderson's collaborative effort with Project Ronin to develop a mobile app, which was launched recently to provide a ready-to-use look-up tool on management of immunotherapy-related toxicities. He is also the course director for Tumor Immunology course at the University of Texas Graduate School of Biomedical Sciences at Houston.